Benzinga | Sep 24, 2020 08:57AM EDT

Chardan Capital Maintains Buy on Forte Biosciences, Raises Price Target to $110

Chardan Capital analyst Gbola Amusa maintains Forte Biosciences (NASDAQ:FBRX) with a Buy and raises the price target from $60 to $110.Chardan Capital analyst Gbola Amusa maintains Forte Biosciences (NASDAQ:FBRX) with a Buy and raises the price target from $60 to $110.